Caprion Teaming Up with Biomarkers Consortium to Study if Biomarkers Can Track Alzheimer’s Progression

Caprion Teaming Up with Biomarkers Consortium to Study if Biomarkers Can Track Alzheimer’s Progression
Caprion Biosciences Inc. is partnering with a public-private organization known as the Biomarkers Consortium to study whether biomarkers can be used to track changes in early Alzheimer’s disease progression. Researchers in the Cerebrospinal Fluid Proteomics Project will measure changes in protein concentration of certain biomarkers over time in Alzheimer’s patients and people with mild cognitive impairment. The

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *